IRulya Therapeutics Inc. Common Stock

About IRulya Therapeutics Inc. Common Stock

IRulya Therapeutics Inc is committed to transforming the lives of patients with serious, underserved diseases by developing disease-modifying therapies. The company is currently developing LAM-001 for the treatment of pulmonary hypertension associated with interstitial lung disease (PH-ILD), bronchiolitis obliterans syndrome post-lung transplant (BOS), and sarcoidosis-associated pulmonary hypertension (SAPH). A Phase 2a study in PH patients has been completed; a Phase 2 clinical study in BOS patients is ongoing; a Phase 2b clinical study in PH-ILD is ongoing; and a Phase 2 clinical study in SAPH is ongoing.